Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER versus PENTACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER versus PENTACEF.
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER vs PENTACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, leading to cell lysis and death. It has activity against both gram-positive and gram-negative bacteria.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g intravenously every 8-12 hours; typical dose 1 g IV q12h for most infections, 2 g IV q8h for severe infections.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
Approximately 2 hours in adults with normal renal function; prolonged to 4–8 hours in mild-to-moderate renal impairment and up to 13–30 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Primarily renal (≥85% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal excretion minimal (<1%).
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic